News
Eli Lilly is in advanced talks to acquire gene editing startup Verve Therapeutics for up to $1.3 billion, aiming to ...
U.S. drugmaker Eli Lilly said on Monday it will offer the higher-dose versions of its popular weight-loss drug Zepbound on ...
5h
Stocktwits on MSNVerve Therapeutics Soars 75% After-Hours Following Report Of $1.3B Eli Lilly Takeover TalksEli Lilly is in late-stage talks to purchase Verve Therapeutics in a transaction that could total $1.3 billion, according to ...
Eli Lilly is unleashing self-pay discounts across the entirety of its obesity portfolio with new price cuts for higher doses ...
(Reuters) -U.S. drugmaker Eli Lilly said on Monday it will offer the higher dose versions of its popular weight-loss drug ...
Eli Lilly and Company (NYSE:LLY) is one of the best stocks to buy for beginners now. On June 11, Eli Lilly announced a ...
Explore more
As part of the deal, Eli Lilly would pay almost $1bn upfront for Verve, which is developing a gene-editing therapy to treat bad cholesterol, and a further $300mn based on the biotech company achieving ...
1don MSN
Eli Lilly ( LLY 0.90%) is one of the undisputed leaders in the fast-growing market for weight-management medicines. Following ...
Eli Lilly will ship the two highest doses of its popular weight-loss drug Zepbound to cash-paying customers on its website ...
Investigators conducted polygraph interviews as part of the effort to determine what happened to Lilly and Jack Sullivan.
Eli Lilly expands Zepbound access with flat-rate pricing and new vial options, supporting wider obesity treatment access ...
An experimental weight-loss drug from Eli Lilly & Co. helped patients lose weight with few side effects, according to the ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results